Yazar "Savas, HA" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Increased nitric oxide and superoxide dismutase levels in euthymic bipolar patients: Impact of past episodes(Federation Amer Soc Exp Biol, 2005) Gergerlioglu, HS; Savas, HA; Armutcu, F; Herken, H; Zoroglu, SS; Tutkun, H; Yilmaz, HR[Abstract Not Available]Öğe Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia?(Karger, 2003) Yanik, M; Vural, H; Kocyigit, A; Tutkun, H; Zoroglu, SS; Herken, H; Savas, HAThe reciprocal regulation of arginase and nitric oxide synthase (NOS) in L-arginine-metabolizing pathways has been demonstrated. There are various evidences of the role of the nitric oxide (NO) in several neuropsychiatric disorders including schizophrenia. However, there is no study which has investigated the role of arginase as an important part of the arginine regulatory system affecting NOS activity in schizophrenia. This study aims to investigate arginase, manganese (Mn) and total nitrite levels (a metabolite of NO) and their relationship to the arginine-NO pathway in patients with schizophrenia. Arginase activities, Mn and total nitrite levels were measured in plasma from 46 patients with schizophrenia and 32 healthy control subjects. Plasma arginase activities and Mn were found to be significantly lower and total nitrite level higher in patients with schizophrenia compared with controls. Our results suggest that the arginine-NO pathway is involved in the pathogenesis of schizophrenia. Copyright (C) 2003 S. Karger AG, Basel.Öğe The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia(Pergamon-Elsevier Science Ltd, 2002) Zoroglu, SS; Herken, H; Yürekli, M; Uz, E; Tutkun, H; Savas, HA; Bagci, CEvidence is accumulating for a possible role of nitric oxide (NO) in schizophrenia. Adrenomedullin (AM) induces vasorelaxation by activating adenylate cyclase and also by stimulating the release of NO. AM immune reactivity is present in the brain consistent with a role as neurotransmitter. We aimed to examine plasma levels of nitrite (a metabolite of NO) and AM in schizophrenic patients. Eighty-two patients with schizophrenia and 21 healthy control subjects were included in this study. DSM-IV diagnosis of chronic schizophrenia was established on the basis of independent structured clinical interviews and review of records by two qualified psychiatrists which included the Brief Psychiatric Rating Scale (BPRS), The Scale for the Assessment of Negative Symptoms (SANS) and The Scale for the Assessment of Positive Symptoms (SAPS). Total nitrite and AM have been studied in plasma. The mean values of plasma nitrite and AM levels in schizophrenic group were significantly higher than control values, respectively (P = 0.03, P < 0.0001). AM levels of schizophrenic patients were three fold higher than controls. In correlation analyses, there were statistically significant positive correlations between AM level and SAPS-delusion subscale (r = 0.27, P = 0.04); SAPS-bizarre behavior subscale (r = 0.28, P = 0.03) and SAPS-total (r = 0.36, P = 0.005). There is no correlation between total nitrite and AM levels (r = 0.11, P = 0.31). Both NO and AM may have a pathophysiological role in schizophrenia, and clinically symptomatology and prognosis of schizophrenia. This subject needs further study including treatment response and subtypes of schizophrenia. (C) 2002 Elsevier Science Ltd. All rights reserved.Öğe Possible role of nitric oxide and adrenomedullin in bipolar affective disorder(Karger, 2002) Savas, HA; Herken, H; Yürekli, M; Uz, E; Tutkun, H; Zoroglu, SS; Özen, MENitric oxide (NO) has been implicated to play a role in the pathogenesis of depressive disorders. Adrenomedullin (AM) induces vasorelaxation by activating adenylate cyclase and also by stimulating the release of NO. AM immune reactivity is present in the brain, consistent with a role as neurotransmitter. Therefore, it is suggested that these two molecules may play a role together in the brain. We aimed to examine AM and NO in bipolar affective disorder (BPAD). Forty-four patients with BPAD and 21 healthy control subjects were included in this study. DSM-IV diagnosis of bipolar affective disorder (type 1, manic episodes) was independently established by two psychiatrists and the Turkish version of the Bech-Rafaelson Mania Scale was administered. Also, a semistructured form was used to ascertain several sociodemographic and clinical variables of the patients. AM and NO were studied in plasma. The mean value of plasma NO levels in the BPAD group of 46.58 +/- 13.97 mumol/l was significantly higher than that of controls (31.81 +/- 8.14 mumol/l) (z = -4.15, p = 0.000). Mean plasma AM levels were found to be increased in patients with BPAD (35.13 +/- 5.26 pmol/l) compared to controls (16.22 +/- 3.02 pmol/l) (z = -6.16, p = 0.000). AM levels of BPAD patients were approximately 2-fold higher than controls. AM levels were positively correlated with the duration of hospitalization for the current episode and negatively correlated with the total duration of illness. Both NO and AM may have a pathophysiological role in BPAD (type I, manic episodes) and the clinical symptomatology and prognosis of BPAD. Copyright (C) 2002 S. Karger AG, Basel.
